Adheron Therapeutics

Adheron Therapeutics is a biotechnology company focused on utilizing pioneering technology that disrupts cell adhesion to treat various diseases. Adheron has developed a new technology that disrupts the adhesion of immune cells through the cell surface protein Cadherin-11 (Cad-11), thereby creating potential therapies for various inflammatory and autoimmune diseases. The company’s humanized monoclonal antibody targeting Cadherin-11, SDP051, has completed the initial phase of clinical development.